0805_Supporting Statement_2024

0805_Supporting Statement_2024.docx

Electronic User Fee Payment Form Requests

OMB: 0910-0805

Document [docx]
Download: docx | pdf


U.S. Food and Drug Administration

Electronic User Fee Payment Form Requests

OMB Control No. 0910-0805 - Extension


SUPPORTING STATEMENT Part A: Justification


Terms of Clearance: None

  1. Circumstances Making the Collection of Information Necessary

This information collection supports Food and Drug Administration (FDA or we) user fee programs. The Government Paperwork Elimination Act (GPEA), Public Law 105-277, title XVII, was signed into law on October 21, 1998. GPEA requires Federal agencies to allow individuals or entities that deal with the agencies the option to submit information or transact business with the agency electronically, when practicable, and to maintain records electronically, when practicable. Its goal is to encourage agencies to incorporate technologically improved respondent reporting as this process typically lowers burden to the respondent.


GPEA allows the FDA to collect information relating to user fee payment refunds and transfer requests. The information contained in the forms is the minimum amount of information required to review and process a refund or transfer request. This electronic submission is intended to reduce the burden for customers to submit a user fee payment refund or transfer request.


To assist respondents with the reporting requirements associated with the information collection, we have developed two forms: Form FDA 3913 entitled, “User Fee Payment Refund Request,” and Form FDA 3914 entitled, “User Fee Payment Transfer Request.”


We therefore request OMB approval of the information collection found in Forms FDA 3913 and 3914, and discussed in this supporting statement.

  1. Purpose and Use of the Information Collection

Forms FDA 3913 facilitate our review and processing of user fee payment refunds. The Form FDA 3913 intends to collect information from respondents who wish to electronically submit a user fee refund request for a duplicate payment, overpayment or for a withdrawn application or submission. Respondents submit organization, contact and payment information. The information is used to determine the reason for the refund, the refund amount and who to contact if there are any questions regarding the refund request. A submission of the User Fee Payment Refund Request form does not guarantee that a refund will be issued.

Form FDA 3914 collects information from respondents who wish to electronically submit a request to transfer a user fee payment from one user fee cover sheet or invoice to another cover sheet or invoice. The information is used to determine the reason for the transfer, how the transfer should be performed and who to contact if we have questions regarding the transfer request. A submission of the User Fee Payment Transfer Request form does not guarantee that a transfer will be performed.

  1. Use of Improved Information Technology and Burden Reduction

Forms FDA 3913 and 3914 leverage existing information technology resources and reduce burden on the submitter. The forms capture all of the required information we need to review and, if applicable, complete either the refund or the transfer. Without the electronic form, submitters provide requests for refund or payment transfer information via other methods that are more time consuming including email, phone and fax.

We estimate that approximately 95 percent of all respondents will submit the information in electronic format.

  1. Efforts to Identify Duplication and Use of Similar Information

We are unaware of duplicative informmation collection.

  1. Impact on Small Businesses or Other Small Entities

The information collection does not impose undue burden on small entitites. User Fee schedules are established by statute and provide for small business determinations. FDA provides guidance to respondents on User Fee schedules and small business determinations on our website at https://www.fda.gov/ForIndustry/UserFees/default.htm.

  1. Consequences of Collecting the Information Less Frequently

The information collection occurs occasionally. The collection of information is dependent on the respondent and ncessary for providing refunds and transfers associated with user fee payments submitted to the agency.

  1. Special Circumstances Relating to the Guidelines of 5 CFR 1320.5

There are no special circumstances for this collection of information.

  1. Comments in Response to the Federal Register Notice and Efforts to Consult Outside the Agency

In accordance with 5 CFR 1320.8(d), FDA published a 60-day notice for public comment in the Federal Register of April 26, 2024 (89 FR 32445). No comments were received.

  1. Explanation of Any Payment or Gift to Respondents

This information collection does not provide for any payment or gift to respondents.


  1. Assurance of Confidentiality Provided to Respondents

In preparing this Supporting Statement, we consulted our Privacy Office to ensure appropriate identification and handling of information collected.


This ICR collects personally identifiable information (PII). PII is collected in the context of the subject individuals’ professional capacity and the FDA-related work they perform for their employer (e.g., point of contact at a regulated entity). The PII submitted via Form FDA 3913 (User Fee Payment Refund Request Form) and Form FDA 3914 (User Fee Payment Transfer Request) is employer identification number, payment identification number, point of contact name, business email address, business telephone number, and business address. FDA determined that although PII is collected, the collection is not subject to the Privacy Act of 1974 and the particular notice and other requirements of the Act do not apply. Specifically, the contractor or FDA does not use name or any other personal identifier to retrieve records from the information collected. Through appropriate form and webpage design, FDA limited submission fields and minimized the PII collected to protect the privacy of the individuals.


Under the Freedom of Information Act (FOIA) (5 U.S.C. 552), the public has broad access to government documents. However, FOIA provides certain exemptions from mandatory public disclosure of government records (5 U.S.C. 552(b)(1-9)). FDA will make the fullest possible disclosure of records to the public, consistent with the rights of individuals to privacy, the property rights of persons in trade and confidential commercial or financial information. The data will be kept private to the extent allowed by law

  1. Justification for Sensitive Questions

FDA collects Employer Identification Numbers (EINs) (also known as a Federal Tax Identification Numbers) for uniquely identifying a business entity. All U.S. organizations must have an EIN to conduct business with the Federal Government. EINs collected may contain social security numbers (SSNs) because some customers are individuals. FDA cannot determine which EINs are SSNs. EINs are required by FDA in order to process payment refunds. A refund cannot be processed by the U.S. Department of the Treasury for a customer without an EIN. As payment refund and transfer requests are voluntary, a customer is providing his/her consent when the customer provides the EIN.


In some circumstances, respondents may be asked to submit proof of payment in the form of a copy of a cancelled check, etc. if a payment cannot be found by FDA. This will be done subsequent to the submission of a user fee payment refund or transfer request. For a refund request, the proof of payment is needed in order to locate the payment, research what happened to the payment and refund the payment. For a transfer request, the proof of payment is needed in order to locate the payment, research what happened to the payment and to apply the payment to the appropriate cover sheet or invoice.



  1. Estimates of Annualized Burden Hours and Costs

12 a. Annualized Hour Burden Estimate


FDA estimates the burden of this collection of information as follows: FDA estimates the burden of this collection of information as follows:



Table 1.--Estimated Annual Reporting Burden1



No. of Respondents

No. of Responses per Respondent

Total Annual Responses

Average Burden per Response

Total Hours

User Fee Payment Refund Request- Form FDA 3913

1,856

1

1,856

0.40

(24 minutes)

742

User Fee Payment Transfer Request- Form FDA 3914

86

1

86

0.25

(15 minutes)

22

Total

764

1 There are no capital costs or operating and maintenance costs associated with this collection of information.


FDA estimates an average of 24 minutes (0.40) per response for user fee payment refund requests under Form FDA 3913, including the time to review instructions, search existing data sources, gather and maintain the data needed, and complete and review the collection of information for payment refunds. The estimated hours are based on past FDA experience with the user fee payment refund request.


In fiscal year 2023, approximately 1,856 user fee refunds were processed for cover sheets and invoices including 2 for Animal Drug User Fees, 2 for Animal Generic Drug User Fees, 3 for Biosimilar Drug User Fees, 1 for Color Additive Certification Fees, 1 for Compounding Quality fees, 32 for Export Certificate Program Fees, 7 for Freedom of Information Act requests, 94 for Generic Drug User Fees, 730 for Medical Device User Fees, 219 for Medical Device Federal Unified Registration and Listing fees, 666 for Mammography inspection fees, 19 for Over-The-Counter Monograph Drug User Fees, 77 for Prescription Drug User Fees, and 3 for Tobacco product fees.


FDA estimates an average of 15 minutes (0.25) per response for user fee payment transfer requests under Form FDA 3914, including the time to review instructions, search existing data sources, gather and maintain the data needed, and complete and review the collection of information. FDA estimated hours are based on past FDA experience with the user fee payment transfer request.


In fiscal year 2023, approximately 86 user fee payment transfers were processed for cover sheets and invoices including 0 for Animal Drug User Fees, 0 for Animal Generic Drug User Fees, 1 for Biosimilar Drug User Fees, 2 for Compounding Quality fees, 4 for Export Certificate Program Fees, 20 for Generic Drug User Fees, 6 for Medical Device User Fees, 37 for Medical Device Federal Unified Registration and Listing fees, 8 for Mammography inspection fees, 8 for Over-The-Counter Monograph Drug User Fees, 0 for Prescription Drug User Fees, and 0 for Tobacco product fees.



12b. Annualized Cost Burden Estimate


FDA assumes that an accountant/bookkeeper at the firm that is requesting the refund or transfer will perform the activities associated with completing Form 3913 and 3914. According to the Department of Labor, Bureau of Labor and Statistics, the average hourly salary for an accountant/bookkeeper position is approximately $30.00, FDA has used this estimate to formulate the cost burden for a firm requesting a refund or transfer. FDA estimates that a firm would make only one refund or transfer request per year.


Type of Respondent

Total Burden Hours

Hourly Wage Rate

Total Respondent Costs

Accountant – refund request

742

$30.00

$22,260

Accountant – transfer request

86

$30.00

$2,580

Total

$24,840

  1. Estimates of Other Total Annual Costs to Respondents and/or Recordkeepers/Capital Costs

There are no additional capital costs associated with this collection of information.

  1. Annualized Cost to the Federal Government

The estimated annualized cost to the Federal Government is $38,609.46. The estimate includes the time it would take FDA to review and process the request. The estimated cost is based on an average grade scale of a GS-13/4 ($46.63/hour) reviewer. The salary estimate does not include benefits and overhead costs.

Type of Respondent

Total Burden Hours

Hourly Wage Rate

Total Respondent Costs

Accountant – refund request

742

$46.63

$34,599.46

Accountant – transfer request

86

$46.63

$4,010.18

Total

$38,609.46



Information collection is funded through existing resource allocations under FDA’s user fee programs.

  1. Explanation for Program Changes or Adjustments

Our estimated burden for the information collection reflects an overall increase of 525 hours and a corresponding increase of 1,274 responses. These are determined by the number of refund/transfer requests received from industry. As the user fee programs mature, processes and procedures utilized by industry also mature, leading to fewer requests for transfers of fees or refunds.

  1. Plans for Tabulation and Publication and Project Time Schedule

There are no tabulated results to publish for this information collection.

  1. Reason(s) Display of OMB Expiration Date is Inappropriate

FDA will display the OMB expiration date as required by 5 CFR 1320.5. 

  1. Exceptions to Certification for Paperwork Reduction Act Submissions

There are no exceptions to the certification.

5


File Typeapplication/vnd.openxmlformats-officedocument.wordprocessingml.document
File Title[Insert Title of Information Collection]
Authorjcapezzu
File Modified0000-00-00
File Created2024-11-02

© 2024 OMB.report | Privacy Policy